CTLA4 and cancer: The development of first-generation immune checkpoint therapies targeting PD-(L)1 or CTLA-4 led to efficient anti-tumor T cell responses, resulting in durable, long-lasting clinical outcomes, but only in a fraction of cancer patients (1–3).